1. Feferman T, Maiti PK, Berrih-Aknin S, Bismuth J, Bidault J, Fuchs S, et al. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. J Immunol. 2005. 174:5324–5331.
Article
2. Huang D, Pirskanen R, Hjelmstrom P, Lefvert AK. Polymorphisms in IL-1beta and IL-1 receptor antagonist genes are associated with myasthenia gravis. J Neuroimmunol. 1998. 81:76–81.
Article
3. Huang DR, Pirskanen R, Matell G, Lefvert AK. Tumour necrosis factor-alpha polymorphism and secretion in myasthenia gravis. J Neuroimmunol. 1999. 94:165–171.
4. Huang D, Liu J, Noren K, Xia SQ, Trifunovic J, Pirskanen R, et al. Genetic association of Ctla-4 to myasthenia gravis with thymoma. J Neuroimmunol. 1998. 88:192–198.
Article
5. Vieira MA, Caillat-Zucman S, Gajdos P, Cohen-Kaminsky S, Casteur A, Bach JF. Identification by genomic typing of non-DR3 HLA class II gene associated with myasthenia gravis. J Neuroimmunol. 1994. 47:115–122.
Article
6. van der Pol WL, Jansen MD, Kuks JB, de Baets M, Leppers-van de Straat FG, Wokke JH, et al. Association of the Fc gamma receptor IIA-R/R131 genotype with myasthenia gravis in Dutch patients. J Neuroimmunol. 2003. 144:143–147.
Article
7. Giraud M, Eymard B, Tranchant C, Gajdos P, Garchon HJ. Association of the gene encoding the delta-subunit of the muscle acetylcholine receptor (CHRND) with acquired autoimmune myasthenia gravis. Genes Immun. 2004. 5:80–83.
Article
8. Bonifati DM, Willcox N, Vincent A, Beeson D. Lack of association between acetylcholine receptor epsilon polymorphisms and early-onset myasthenia gravis. Muscle Nerve. 2004. 29:436–439.
Article
9. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med. 1998. 338:436–445.
Article
10. Zhao X, Gharizadeh B, Hjelmstrom P, Pirskanen R, Nyren P, Lefvert AK, et al. Genotypes of CCR2 and CCR5 chemokine receptors in human myasthenia gravis. Int J Mol Med. 2003. 12:749–753.
Article
11. Strieter RM, Standiford TJ, Huffnagle GB, Colletti LM, Lukacs NW, Kunkel SL. "The good, the bad, and the ugly." The role of chemokines in models of human disease. J Immunol. 1996. 156:3583–3586.
12. Miyagishi R, Kikuchi S, Takayama C, Inoue Y, Tashiro K. Identification of cell types producing RANTES, MIP-1 alpha and MIP-1 beta in rat experimental autoimmune encephalomyelitis by in situ hybridization. J Neuroimmunol. 1997. 77:17–26.
Article
13. Favorova OO, Andreewski TV, Boiko AN, Sudomoina MA, Alekseenkov AD, Kulakova OG, et al. The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4-positive Russians. Neurology. 2002. 59:1652–1655.
Article
14. Saito R, Onodera H, Tago H, Suzuki Y, Shimizu M, Matsumura Y, et al. Altered expression of chemokine receptor CXCR5 on T cells of myasthenia gravis patients. J Neuroimmunol. 2005. 170:172–178.
Article
15. Petrek M, Drabek J, Kolek V, Zlamal J, Welsh KJ, Bunce M, et al. CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. Am J Respir Crit Care Med. 2000. 162:1000–1003.
Article
16. Wang FS, Hong WG, Cao Y, Liu MX, Jin L, Hu LP, et al. Population survey of CCR5 delta32, CCR5 m303, CCR2b 64I, and SDF1 3'A allele frequencies in indigenous Chinese healthy individuals, and in HIV-1-infected and HIV-1-uninfected individuals in HIV-1 risk groups. J Acquir Immune Defic Syndr. 2003. 32:124–130.
Article
17. De Pinho Lott Carvalhaes FA, Cardoso GL, Hamoy IG, Liu YT, Guerreiro JF. Distribution of CCR5-delta32, CCR2-64I, SDF1-3'A mutations in populations from the Brazilian Amazon Region. Hum Biol. 2004. 76:643–646.
18. Gharagozloo M, Doroudchi M, Farjadian S, Pezeshki AM, Ghaderi A. The frequency of CCR5Delta32 and CCR2-64I in southern Iranian normal population. Immunol Lett. 2005. 96:277–281.
Article
19. Oh MD, Kim SS, Kim EY, Lee S, Kim N, Park KY, et al. The frequency of mutation in CCR5 gene among Koreans. Int J STD AIDS. 2000. 11:266–267.
Article
20. Martison JJ, Hong L, Karanicolas R, Moore JP, Kostrikis LG. Global distribution of the CCR2-64I/CCR5-59653T HIV-1 disease-protective haplotype. AIDS. 2000. 14:483–489.
Article
21. Poea-Guyon S, Christadoss P, Le Panse R, Guyon T, De Baets M, Wakkach A, et al. Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J Immunol. 2005. 174:5941–5949.
Article
22. Shi FD, Zhang GX, Bai XF, Van der Meide PH, Link H. Cellular mRNA expression of interferon-gamma (IFN-gamma), IL-4 and IL-10 relates to resistance to experimental autoimmune myasthenia gravis (EAMG) in young Lewis rats. Clin Exp Immunol. 1997. 108:523–528.
Article
23. Reyes-Reyna S, Krolick KA. Chemokine production by rat myocytes exposed to interferon-gamma. Clin Immunol. 2000. 94:105–113.
24. Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ, Coughlin SR. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc Natl Acad Sci U S A. 1994. 91:2752–2756.
Article
25. Gu D, Wogensen L, Calcutt NA, Xia C, Zhu S, Merlie JP, et al. Myasthenia gravis-like syndrome induced by expression of interferon gamma in the neuromuscular junction. J Exp Med. 1995. 181:547–557.
Article
26. Rottman JB, Ganley KP, Williams K, Wu L, Mackay CR, Ringler DJ. Cellular localization of the chemokine receptor CCR5. Correlation to cellular targets of HIV-1 infection. Am J Pathol. 1997. 151:1341–1351.
27. Reyes-Reyna S, Stegall T, Krolick KA. Muscle responds to an antibody reactive with the acetylcholine receptor by up-regulating monocyte chemoattractant protein 1: a chemokine with the potential to influence the severity and course of experimental myasthenia gravis. J Immunol. 2002. 169:1579–1586.
Article
28. Broder CC, Collman RG. Chemokine receptors and HIV. J Leukoc Biol. 1997. 62:20–29.
Article
29. Siebert H, Sachse A, Kuziel WA, Maeda N, Bruck W. The chemokine receptor CCR2 is involved in macrophage recruitment to the injured peripheral nervous system. J Neuroimmunol. 2000. 110:177–185.
Article
30. Galimberti D, Fenoglio C, Lovati C, Gatti A, Guidi I, Venturelli E, et al. CCR2-64I polymorphism and CCR5 Delta32 deletion in patients with Alzheimer's disease. J Neurol Sci. 2004. 225:79–83.
Article
31. Drachman DB, Adams RN, Josifek LF, Self SG. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med. 1982. 307:769–775.
Article